← Patent-cliff monitor small molecule BALVERSA ERDAFITINIB
Loss of exclusivity February 2038 latest FDA-listed patent expiry
Drug detail Brand name BALVERSA Active ingredient ERDAFITINIB Strength 5MG Dosage form TABLET Route ORAL Modality Small molecule FDA approval April 2019 Marketing status RX
Listed patents Patent Expires Type 11077106 February 2038 use U-3808 10478494 August 2036 use U-3902 12678498 June 2036 use U-4584 10898482 February 2036 product 11684620 February 2036 use U-3806 12037644 October 2035 use U-3972 9902714 March 2035 product 8895601 April 2033 substance, product 9464071 April 2031 use U-3805
Regulatory exclusivity Code Expires I-930 January 2027
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.